Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
To document the clinical activity of imatinib mesyalte in a child with a dermatofibrosarcoma protuberans (DFSP). An 18-month-old girl presented with a large extremity DFSP. As surgical resection would have caused unacceptable functional defects, imatinib mesylate was administered to induce tumor reduction and or stabilization. After 23 weeks of therapy, magnetic resonance imaging (MRI) of the tumor showed a reduction in the subcutaneous thickness in the transverse plane. The drug was tolerated well without any adverse reactions. Imatinib mesylate offers a non-surgical alternative for the treatment of large DFSP in children.
Price
Victoria E
VE
Department of Pediatrics, Division Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Fletcher
Jonathan A
JA
Zielenska
Maria
M
Cole
William
W
Viero
Sandra
S
Manson
David E
DE
Stuart
Mary
M
Pappo
Alberto S
AS
D001549:Benzamides; D018223:Dermatofibrosarcoma / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007223:Infant; D007866:Leg / Q000473:pathology; D008279:Magnetic Resonance Imaging; D010879:Piperazines / Q000627:therapeutic use*; D020574:Proto-Oncogene Proteins c-sis / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D047368:Tumor Burden / Q000187:drug effects
D001549:Benzamides; D010879:Piperazines; D020574:Proto-Oncogene Proteins c-sis; D011743:Pyrimidines; D000068877:Imatinib Mesylate